Trong khi , mt s ngi khc li thy ung vo ba tra hoc ba ti s tt hn vi h
Cardiovascular Protection: Major clinical trials like the LEADER trial for liraglutide have shown that GLP-1 RAs can significantly reduce the risk of major adverse cardiovascular events, such as heart attacks and strokes, in patients with type 2 diabetes
Natural fibers like wool and cotton offer superior warmth
While some individuals can meet their B12 needs through diet, others may require supplements to boost their levels
GLP-1 receptor agonists may be appropriate for individuals who: Have a body mass index (BMI) of 35 kg/m or higher (or lower thresholds32.5 kg/m or abovefor people from Black, Asian, and other minority ethnic groups) and would benefit from weight loss Have established cardiovascular disease or are at high cardiovascular risk (certain GLP-1 receptor agonists have demonstrated cardiovascular benefits in clinical trials) Have chronic kidney disease (CKD) or heart failure, where specific agents may offer additional protection Require additional glucose-lowering therapy but wish to avoid weight gain associated with some other diabetes medicines Cannot tolerate or have contraindications to other glucose-lowering therapies NICE NG28 continuation criteria : GLP-1 receptor agonist therapy should be continued beyond 6 months only if the person has had a beneficial metabolic response , defined as a reduction of at least 11 mmol/mol (1.0%) in HbA1c and a weight loss of at least 3% of initial body weight
Additionally, individuals with a history of certain health conditions or sensitivities to medication may respond differently to each drug, making it important to discuss any potential concerns with a healthcare provider
